The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?

Autor:	Aitken, Samuel L, Pierce, Virginia M, Pogue, Jason M, Kline, Ellen G, Tverdek, Frank P, Shields, Ryan K
Předmět:	ENZYME metabolism COMBINATION drug therapy MICROBIAL sensitivity tests BETA lactam antibiotics ESCHERICHIA coli ESCHERICHIA coli diseases GENETIC mutation BETA lactamases AZTREONAM CEPHALOSPORINS
Zdroj:	Clinical Infectious Diseases; 10/15/2024, Vol. 79 Issue 4, p834-837, 4p
Abstrakt:	We report identification of 5 patients with infections caused by NDM-5-producing Escherichia coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu